Axomadol

DB16100InvestigationalSmall molecule

Axomadol is under investigation in clinical trial NCT01043263 (Efficacy and Safety of EN3324 (Axomadol) in Subjects With Chronic Low Back Pain).

Mechanism: Pharmacologically active on Delta-type opioid receptor, Kappa-type opioid receptor, and Mu-type opioid receptor
Curator reviewed
Formula / weight: C₁₆H₂₅NO₃ · 279.38 g/mol (avg)
Also known as: Bn-110 free base · Bn110 free base · Grt-151 free base · Grt151 free base

Resolves to

Compound

Structure

InChIKeyLQJLLAOISDVBJM-OFQRWUPVSA-NSMILESCOC1=CC=CC(=C1)[C@]1(O)C[C@@H](O)CC[C@H]1CN(C)C

Targets

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Axomadol, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.